Skip to content

LYSERGIC ACID DIETHYLAMIDE (LSD-25)

Charles Savage

American Journal of Psychiatry June 1, 1952 DOI: 10.1176/ajp.108.12.896 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Sample size 15
Population Patients with depressive reactions
Intervention Lysergic acid diethylamide (LSD-25 Sandoz)
Dose 20-100 micrograms
Duration One month's treatment
Topics Anxiety LSD
Keywords Euphoriant Depersonalization Derealization Feeling Hallucinogen Clinical psychology
Citations 137
Key findings Improvement during LSD therapy was not greater than that obtained without its use in comparable cases, but LSD affords therapeutically valuable insights into unconscious processes through hallucinations.

Abstract

Lysergic acid diethylamide (LSD-25 Sandoz) given orally in single doses as low as 20 micrograms produces depersonalization, derealization, and increased imagery in "normal" individuals. Larger doses are required to produce the same effect in psychotic patients. Of 15 patients with depressive reactions, 3 recovered and 4 improved after one month's treatment with daily oral doses of 20-100 micrograms of LSD. Four patients showed no improvement. In 4 cases, treatment was discontinued before proper evaluation could be made. Anxiety was a prominent reaction while less frequently euphoria was observed. In 3 patients who developed euphoria it served as an aid to psychotherapy by encouraging expression of feeling. In the others the heightened anxiety encouraged reticence rather than confidence. Improvement obtained during the course of LSD therapy was not greater than that obtained without its use in comparable cases. However, LSD affords therapeutically valuable insights into unconscious processes by the medium of the hallucinations it produces.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Improvement during LSD therapy was not greater than that obtained without its use in comparable cases, and anxiety was a prominent reaction during treatment.

    Synthesized

Comparable studies

Other observational and cohort studies on LSD for anxiety, most cited first.

Study Year Design Participants
Psychedelics not linked to mental health problems or suicidal behavior: A population study Randomly selected United States adults 2015 Observational cohort n = 135,095
Long-lasting subjective effects of LSD in normal subjects Healthy participants 2017 Observational cohort n = 16
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure. Adult survivors of a single large-scale terrorist attack at a festival 2025 Observational cohort n = 343
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. Adults with treatment-resistant depressive and/or anxiety disorders 2026 Retrospective observational cohort n = 115
Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study Patients with treatment-resistant depression or anxiety disorders treated under... 2025 Retrospective observational study n = 30

Explore topics

By condition and practice